人福医药子公司撤回重组质粒-肝细胞生长因子注射液注册申请

Core Viewpoint - The company, Renfu Pharmaceutical, has decided to voluntarily withdraw its drug registration application for the recombinant plasmid-hepatocyte growth factor injection after receiving a termination notice from the National Medical Products Administration [1] Group 1: Company Actions - Renfu Pharmaceutical's subsidiary, Wuhan Guanggu Renfu Biopharmaceutical Co., Ltd., received a notice allowing the withdrawal of the registration application [1] - The company stated that the decision to withdraw was made after careful consideration of the latest review status of the project [1] - Following the withdrawal, the company plans to thoroughly evaluate and improve the research data before resubmitting the application in accordance with regulatory and technical requirements [1] Group 2: Project Status - The withdrawal of the registration application does not signify the termination of the project [1]